source
- Early-stage data show promise for targeting Wnt/β-catenin pathway across cancersEarly-stage clinical results from the company and several peers indicate that the Wnt/β-catenin signaling pathway could become a viable target for treating a range of tumor types. The pathway has…
- Aspen Neuroscience and Bambusa raise $310M combined in IPOsAspen Neuroscience, a biotech focused on cell therapy for Parkinson's disease, announced it will raise about $141 million through its initial public offering scheduled for Friday. Bambusa, a start…